261 related articles for article (PubMed ID: 23935499)
21. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
22. Identification of mutations in a candidate dengue 4 vaccine strain 341750 PDK20 and construction of a full-length cDNA clone of the PDK20 vaccine candidate.
Kelly EP; Puri B; Sun W; Falgout B
Vaccine; 2010 Apr; 28(17):3030-7. PubMed ID: 19874927
[TBL] [Abstract][Full Text] [Related]
23. Review of dengue virus and the development of a vaccine.
Murrell S; Wu SC; Butler M
Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
[TBL] [Abstract][Full Text] [Related]
24. Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by
Dietrich EA; Ong YT; Stovall JL; Dean H; Huang CY
Am J Trop Med Hyg; 2017 Nov; 97(5):1423-1427. PubMed ID: 28820715
[TBL] [Abstract][Full Text] [Related]
25. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
Simmons M; Burgess T; Lynch J; Putnak R
Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
[TBL] [Abstract][Full Text] [Related]
26. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
Whitehead SS; Hanley KA; Blaney JE; Gilmore LE; Elkins WR; Murphy BR
Vaccine; 2003 Oct; 21(27-30):4307-16. PubMed ID: 14505913
[TBL] [Abstract][Full Text] [Related]
27. T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification.
Pinto PBA; Assis ML; Vallochi AL; Pacheco AR; Lima LM; Quaresma KRL; Pereira BAS; Costa SM; Alves AMB
Front Immunol; 2019; 10():1522. PubMed ID: 31333657
[TBL] [Abstract][Full Text] [Related]
28. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.
Velzing J; Groen J; Drouet MT; van Amerongen G; Copra C; Osterhaus AD; Deubel V
Vaccine; 1999 Mar; 17(11-12):1312-20. PubMed ID: 10195766
[TBL] [Abstract][Full Text] [Related]
29. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
31. Next-generation dengue vaccines: novel strategies currently under development.
Durbin AP; Whitehead SS
Viruses; 2011 Oct; 3(10):1800-14. PubMed ID: 22069516
[TBL] [Abstract][Full Text] [Related]
32. Development of a live attenuated dengue virus vaccine using reverse genetics.
Blaney JE; Durbin AP; Murphy BR; Whitehead SS
Viral Immunol; 2006; 19(1):10-32. PubMed ID: 16553547
[TBL] [Abstract][Full Text] [Related]
33. Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
Strouts FR; Popper SJ; Partidos CD; Stinchcomb DT; Osorio JE; Relman DA
PLoS Negl Trop Dis; 2016 May; 10(5):e0004731. PubMed ID: 27214236
[TBL] [Abstract][Full Text] [Related]
34. Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon.
Bustos-Arriaga J; Gromowski GD; Tsetsarkin KA; Firestone CY; Castro-Jiménez T; Pletnev AG; Cedillo-Barrón L; Whitehead SS
Vaccine; 2018 Jun; 36(24):3460-3467. PubMed ID: 29752023
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
[TBL] [Abstract][Full Text] [Related]
36. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
Martinez DR; Metz SW; Baric RS
Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
[TBL] [Abstract][Full Text] [Related]
37. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
38. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
39. Targeted mutagenesis as a rational approach to dengue virus vaccine development.
Blaney JE; Durbin AP; Murphy BR; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():145-58. PubMed ID: 19802584
[TBL] [Abstract][Full Text] [Related]
40. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
